Drugs / BAY2433334
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05419635 | Jun 2022 → May 2023 | acute myocardial infarction, atrial fibrillation, ischemic stroke, venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04510987 | Aug 2020 → Sep 2021 | venous thromboembolism | Bayer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04304534 | Jun 2020 → Feb 2022 | acute myocardial infarction | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT04304508 | Jun 2020 → Feb 2022 | stroke disorder | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT04218266 | Jan 2020 → Oct 2021 | atrial fibrillation | Bayer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05686070 | Jan 2023 → Oct 2025 | transient ischemic attack | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT05643573 | Dec 2022 → Jan 2024 | atrial fibrillation | Bayer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2433334 | “Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs...” PMID 36063821 ↗ Sep 20228“Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack” NCT04304534 ↗ “Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban” NCT05643573 ↗ “Oral FXIa Inhibitor Asundexian (BAY 2433334)” NCT05686070 ↗ “Asundexian (BAY2433334)” NCT05419635 ↗ |
| Known as | asundexian | “Eligible participants were randomly assigned (1:1:1:1), using an interactive web-based response system and stratified according to anticipated antiplatelet therapy (single vs...” PMID 36063821 ↗ Sep 20224“A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse...” PMID 36030390 ↗ Aug 2022 |
| Action | Inhibit | “factor XIa (FXIa) inhibitor” PMID 36063821 ↗ Sep 2022 |
| Modality | Small molecule | “an oral small molecule factor XIa (FXIa) inhibitor” PMID 36063821 ↗ Sep 2022 |
| Route | Oral | “Tablet, taken orally once a day.” NCT04304508 ↗ |